Published Date:2024-01-30 Original Link:https://www.onenessbio.com/en/news_detail263_5.htm No 1 Date of announcement 2024/01/30 Time of announcement 17:57:11 Subject Submission of a phase II clinical trial protocol for subcutaneous injection formulation of FB825 in patients with moderate-to-severe atopic dermatitis To which item it meets paragraph 10 Date of events 2024/01/30 Statement Product: Subcutaneous injection formulation of FB825, Anti-CεmX monoclonal...Read More